Last reviewed · How we verify
NCT05681156
Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol
trial testing N/A- There is no intervention. in Streptococcus Pneumoniae Infection in 199 participants. Completed in 8 September 2023.
23 March 2023
Quick facts
| Lead sponsor | Meridian Bioscience, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 199 |
| Start date | 1 February 2023 |
| Primary completion | 23 March 2023 |
| Estimated completion | 8 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- N/A- There is no intervention.
Conditions studied
- Streptococcus Pneumoniae Infection — all drugs for Streptococcus Pneumoniae Infection →
- Legionella Pneumophila Serogroup 1 Infection — all drugs for Legionella Pneumophila Serogroup 1 Infection →
Sponsor
Meridian Bioscience, Inc. — full company profile →
Who can join
18 and older, any sex, with Streptococcus Pneumoniae Infection or Legionella Pneumophila Serogroup 1 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Beta trial to evaluate the preliminary clinical performance of the Curian S. pneumo/Legionella assay for its use in the qualitative detection of Streptococcus pneumoniae and/or Legionella pneumophila serogroup 1 antigens in human urine specimens.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05681156
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Streptococcus Pneumoniae Infection
Currently open trials in the same condition.
- NCT05759520 — Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants · Phase 3 · active not recruiting
Other Meridian Bioscience, Inc. trials
Trials by the same sponsor.
- NCT03680898 — Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Ge · NA · unknown
- NCT03611101 — Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials · completed
- NCT03422341 — Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs. · NA · completed
- NCT03251261 — Detection of Cytomegalovirus Virus in Neonates · completed
- NCT03462576 — Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05681156 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meridian Bioscience, Inc.
- Last refreshed: 29 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05681156.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing